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1. Introduction
Cardiovascular disease (CVD) is a most common complication and a chief cause of death in pa‐
tients with end stage renal disease (ESRD) accounting for 45% to 50% of causes of death in ESRD
patients. In ESRD patients, mortality due to CVD is 10~30 times higher than in the general pop‐
ulation. 80% patients on maintenance homodialysis (MHD) had cardiovascular complication.
In Chinese patients, the prevalence of CVD in young MHD patients was as high as 63.8%, and its
characteristics were similar to middle- and old-aged MHD patients. This is likely due to ventric‐
ular hypertrophy as well as nontraditional risk factors, such as chronic volume overload, ane‐
mia, inflammation, oxidant stress, homocysteine and other aspects of the uremic milieu. China
collaborative study on dialysis: a multi-centers cohort study on cardiovascular diseases in pa‐
tients on maintenance dialysis showed that cardiovascular morbidity during chronic dialysis
was more prevalent in peritoneal dialysis (PD) than HD patients among those with old age and
long-term dialysis. Metabolic disturbance-related risk factors were independently associated
with CVD only in PD patients. Better understanding the impact of dialysis modality on CVD
would be an important step for prevention and treatment [1]. In this chapter we focus on epi‐
demiology and management of traditional and nontraditional CVD risk fators and on ischemic
heart disease, heart failure and arrhythmia.
2. Traditional risk factors
2.1. Hypertension
2.1.1. Epidemiology and pathophysiology
Hypertension is a common complication in patients with chronic kidney disease. The inci‐
dence of hypertension grows along with the decrease in glomerular filtration rate (GFR). It
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was reported that the incidence of hypertension in patients with GFR less than 60 ml/min
was 50%-75%. However, the incidence of hypertension was extraordinarily higher in MHD
patients. In 69 dialysis units in the United States, almost 86% of MHD patients were suffer‐
ing from hypertension, and the control rate for their BP was merely 30%[2]. Hypertension is
a significant risk factor for cardiovascular disease in MHD patients. Foley et al [3] found that
with each 10 mm Hg increase of BP in MHD patients, the risk of LVH increased by 48%,
ischemic heart disease increased by 39% and congestive cardiac failure increased by 44%.
The causes of hypertension in MHD patients are miscellaneous, including volume overload
[4], activation of the RAS [5], sympathetic hyperactivity [6] and increases in inhibitors of ni‐
tric oxide (NO) in the blood circulation, such as ADMA [7]- which result in a high incidence
of hypertension and difficulties in BP control. MHD patients always need to be treated with
combinations of 3 or more categories of antihypertensive drugs.
2.1.2. Definition and drug therapy
a. Definition: Predialysis systolic pressure >140mmHg and/or diastolic pressure
>90mmHg when the patient is believed to be at so-called “dry weight”.
b. Drug Therapy goal: Arterial pressure goals should be established individually, taking
into account age, comorbid conditions, cardiac function, and neurologic status. In pa‐
tients with raised systolic and diastolic pressure and few background cardiovascular
complications, a reasonable predialysis BP goal is <130/80mmHg, that targeted by JNC7
for patients with chronic renal disease. In patients with isolated systolic hypertension
and wide pulse pressure (usually elderly patients with atherosclerotic complications),
excessive lowering of BP may be hazardous. For them a target predialysis systolic pres‐
sure of about 140-150mmHg is prudent.
2.1.3. Treatment
a. Sodium and fluid restricton. Most fluid ingestion is driven by salt ingeston. Sodium re‐
striction of 2g per day(87mmol) should not be onerous, and of the patient is open to a
more stringent sodium restriction and caloric and protein intake seem adequate, then
this should be encouraged.
b. Longer and/or more frequent/longer dialysis sessions. In some ESRD patients, a regular
dialysis schedule, three times per week using 4-hour session lengths will be insufficient
to maintain euvolemia. In such patients, the choics are to increase the dialysis session
length, or to switch to a four times per week, or even daily dialysis[8].
c. Antihypertensive drug use
The regular antihypertensive drugs in MHD patients include angiotensin-converting enzyme
inhibitor (ACEI) or angiotensin receptor blocker (ARB), calcium channel blocker (CCB) and β-
receptor blocker or α-receptor blocker. The Avoiding Cardiovascular Events through Combi‐
nation Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial showed
that initial antihypertensive therapy with benazepril plus amlodipine was superior to benaze‐
pril plus hydrochlorothiazide in reducing cardiovascular morbidity and mortality.
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The ACCOMPLISH trial [9] was a 3-year multicenter, event-driven trial involving patients
with high cardiovascular risk who were randomized in a double-blinded manner to benaze‐
pril plus either hydrochlorothiazide or amlodipine and titrated in parallel to reach recom‐
mended blood pressure goals. Of the 8125 participants in the United States, 1414 were of self-
described Black ethnicity. The composite kidney disease end point, defined as a doubling in
serum creatinine, end-stage renal disease, or death was not different between Black and non-
Black patients, although the Blacks were significantly more likely to develop a greater than
50% increase in serum creatinine to a level above 2.6 mg/dl. They found important early differ‐
ences in the estimated glomerular filtration rate (eGFR) due to acute hemodynamic effects, in‐
dicating that benazepril plus amlodipine was more effective in stabilizing eGFR compared to
benazepril plus hydrochlorothiazide in non-Blacks. There was no difference in the mean eGFR
loss in Blacks between therapies. Thus, benazepril coupled to amlodipine was a more effective
antihypertensive treatment than when coupled to hydrochlorothiazide in non-Black patients
to reduced kidney disease progression. Blacks have a modestly higher increased risk for more
advanced increases in serum creatinine than non-Blacks.
A recent research in China showed that the nitrate can decrease BP, reduce the total catego‐
ries and quantities of other antihypertensive drugs needed, reverse LVH modeling and re‐
duce the rate of acute heart failure in MHD patients, with good tolerance and safety, by the
release of NO which is probably antagonized by ADMA in ESRD subjects. It is, therefore,
appropriate to consider sustained-release nitrates as the sixth category of antihypertensive
drugs for MHD patients, in addition to ACEIs and ARBs, CCBs, β-receptor blockers and α-
receptor blockers [10].
2.2. Smoking
Smoking is associated with progression early-stage CKD patients, and may well adversely im‐
pact residual renal function in dialysis patients [11]. Smoking strongly associates with inci‐
dent heart failure, incident peripheral vascular disease, and all-cause mortality in the U.S.
Renal Data System (USRDS). Post hoc analysis of the HEMO Study in patients with available
comorbidity, clinical, and nutritional data. The results showed that 17% were current smokers
and 32% were former smokers at baseline. After case-mix adjustment, compared with never
smoking, current smoking was associated with greater infection-related mortality (hazard ra‐
tio [HR], 2.04; 95% confidence interval [CI], 1.32-3.10) and all-cause mortality (HR, 1.44; 95%
CI, 1.16-1.79) and greater cardiovascular (incidence rate ratio [IRR], 1.49; 95% CI, 1.22-1.82) and
all-cause (IRR, 1.43; 95% CI, 1.24-1.65) hospitalization rates. The population attributable frac‐
tion (i.e., fraction of observed deaths that may have been avoided) was 5.3% for current smok‐
ers versus never-smokers and 2.1% for current versus former smokers [12].
2.3. Diabetes
Diabetics are at higher risk for acute coronary syndromes. Additionally, there is increased
prevalence of heart failure. Poor blood glucose control is associated with increased mortality
in dialysis patients [13]. NKF-K/DOQI guidelines recommend a target HbA1c of <7% for pa‐
tients with DM and CKD[14]. A prospective interventional study in patients with DM but
Cardiovascular Disease in Hemodialysis Patients
http://dx.doi.org/10.5772/53071
5
without renal failure showed an increase in all-cause mortality in patients with HbA1c <6%
attained by intensive therapy compared to the standard therapy group[15]. Nonetheless
some small observational studies mostly performed in Asian populations indicate the im‐
portance of good glycemic control for survival in dialysis patients with DM [16,17,18]. One
observational study from Germany found higher HbA1c values to be a risk factor for all-
cause mortality and cardiovascular disease[19]. However, in several studies no association
between HbA1c and neither patient survival[20,21,22] nor cardiovascular disease [23] could
be shown in dialysis patients with DM. Most of these studies were based on a single meas‐
urement of HbA1c values. Only two studies considered time-dependent analyses using all
available measurements of HbA1c during the whole observation period instead of using on‐
ly a baseline measurement [24]. Insulin resistance (IR) is highly prevalent in MHD patients
and is associated with poor cardiovascular outcomes. Hyperinsulinemic euglycemic glucose
clamp (HEGC) is the gold standard for measuring IR. An observational study in USA found
that eighty-three percent of the subjects displayed either glucose intolerance or overt insulin
resistance by HEGC (GDR median, 5.71; interquartile range [IQR], 4.16, 6.81). LAR and HO‐
MA-AD were the best correlates of IR measured by HEGC (r=-0.72, P<0.001, and -0.67,
P<0.001), respectively. Fat percentage, interleukin-6, and adipokines (leptin, adiponectin,
and resistin) were strongly associated with GDR. HEGC, LAR, and HOMA-AD had the best
intraclass correlation coefficients [25].
2.4. Dyslipidemia.
Dyslipidemia is a well-established metabolic disorder in dialysis patients. A recent study
[26] found that a significant increase of serum triglycerides (p= 0.002), lipoprotein (a) (p =
0.001) and C Reactive Protein (p = 0.008) was observed in patients when compared with
healthy controls. A significant decrease of serum total cholesterol (p=0.01), HDLcholesterol
(p<0.001), LDL-cholesterol (p=0.005) and apolipoprotein AI (p<0.001) was also observed in
patients. A study of cholesterol metabolism in patients with hemodialysis in the presence or
absence of coronary artery disease showed that HD patients showed lower cholesterol con‐
centrations than non-HD patients, and, as compensation, their cholesterol absorption might
be accelerated. However, higher cholesterol synthesis, which was correlated with higher
BMI, might be an independent predictor for the presence of coronary artery disease in HD
patients [27].
2.4.1. Cholesterol
In dialysis, the relationship of total or low-density lipoprotein (LDL) cholesterol to mootality
is U-shaped; patients with LDL cholesterol levels above 100 mg/dL (2.6 mmol/L) are most
likely at increased risk for adverse cardiovascular outcomes, but low levels, probably indi‐
cating malnutrition, also are associated with higher mortality rates. Despite frequently re‐
duced levels total and LDL cholesterol, atherogenic lipoprotein remnants and lipoprotein (a)
are generally increased and high-density lipoprotein (HDL) cholesterol levels are generally
reduced, likely contributing to CVD risk. On the other hand, Dialysis per se have neutral ef‐
fects on serum lipid profile, however, certain dialysis-related parameters may have signifi‐
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cant affect on lipoprotein metabolism and modify the feature of dyslipidemia in
hemodialysis (HD) patients. These parameters include; membrane used in dialyzer (high
flux vs. low flux), type of dialyzate (bicarbonate vs. acetate), anticoagulant (heparin) and the
phosphate-binder (sevelamer hydrochloride). The use of high-flux polysulfone or cellulose
triacetate membranous instead of low-flux membrane is associated with a significant reduc‐
tion in triglyceride levels and an increase in apolipoprotein Al and HDL-cholesterol lev‐
els[28].The use of bicarbonate dialyzate may result in higher HDL-cholesterol concentrations
than the use of acetate dialysate[29]. Chronic use of heparin as an anticoagulant releases lip‐
oprotein lipase from the endothelial surface which may result in lipoprotein lipase depletion
and defective catabolism of triglyceride rich-lipoprotein. Finally sevelamer hydrochloride
significantly reduces the concentration of total cholesterol and apolipoprotein-b in HD pa‐
tients[30].
2.4.2. Hypertriglyceridemia
Nearly one third of dialysis patients have hypertriglyceridemia, defined by levels above 200
mg/dL (2.26 mmollL), with levels occasionally up to 600 mg/dL (6.8 mmol/L). The predomi‐
nant underling cause is a deficiency of lipoprotein lipase, resulting in reduced lipolysis of
triglyceride (TG)-rich very low-density lipoproteins (VLDLs) and yielding high quantities of
atherogenic remnant lipoproteins. Enrichment of LDL particles with triglycerides also sug‐
gests partial deficiency of hepatic lipase.
2.4.3. Measurement
If possible, dialysis patients should be evaluated with a fasting (although perhaps recom‐
mended we know not practical) serum lipid panel that includes total and HDL cholesterol
as well as triglycerides.
a. LDL cholesterol. LDL cholesterol is commonly computed by subtracting the serum tri‐
glyceride level divided either by 5 (when TGs are measured in mg/dL) or by 2.19 (when
TGs are measured in mmol/L) as well as the HDL cholesterol level from the total choles‐
terol.
b. Atherogenic, remnant lipoproteins and non-HDL cholesterol. In persons without elevat‐
ed triglyceride levels (TG<200 mg/dL or 2.26 mmol/L), levels of atherogenic remnant
lipoproteins correlate well with the calculated LDL cholesterol. When 200 <TG <500
mg/dL (2.26 <TG <5.64 mmol/L), levels of atherogenic remnant lipoproteins correlate
well with VLDL levels.
2.4.4. Treatment
a. Target lipid levels. Because dialysis patients the highest risk group for CVD events, cur‐
rent KDOQI guidelines recommend that dyslipidemia shouldbe more aggressively
treated than in the general population, with an LDL cholesterol target level below 100
mg/dL (2.6 mmol/L). Even lower LDL targets (70 mg/dL or 1.8 mmol/L) have been ad‐
vocated in diabetic patients during the earlier stages of CKD based on extrapolation
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from resuIts in nonuremic individuals. However, there is no direct trial evidence to
support these lower LDL targets in diabetic patients with any srage of CKD. Treatment
of very high TG levels (>500 mg/dl or 5.7 mmol/L) is recommended to protect against
TG pancreatitis.
b. Drug (statins) therapy. Statins (HMG-CoA Reductase inhibitor) are the most commonly
prescribed agents for the treatment of hypercholesterolemia. Statins primarily inhibit
hepatic cholesterol biosynthesis through inhibition of HMG-CoA reductase. The net ef‐
fect of statins administrations are reduction in serum total cholesterol and LDL-choles‐
terol, modest reduction in serum TG and modest elevation in serum HDL. Statins have
multiple pleiotropic effects beside their significant cholesterol lowering effect. They in‐
clude; reduction of proteinuria in human[31], anti-inflammatory effect and reduction of
fibrosis of tubular cells. Treatment with HMG-CoA reductase inhibitors is associated
with the attenuation of progression of atherosclerosis and reduction in cardiovascular
and cerebrovascular events. The beneficial effects of statins are observed at the endothe‐
lial level, displayed by atherosclerotic plaque stabilization and in some case plaque re‐
gression[32]. The potential adverse effects associated with statin therapy are important
to consider in the management of dyslipidemia in patients with ESRD. An recent study
of Heart and Renal Protection showed that reduction of LDL cholesterol with simvasta‐
tin 20 mg plus ezetimibe 10 mg daily safely reduced the incidence of major atheroscler‐
otic events in a wide range of patients with advanced chronic kidney disease [33].
3. Nontraditional risk factors
3.1. Chronic volume overload
Volume overload is a common manifestation in MHD patients [34]. Volume overload can in‐
crease returned blood volume, cardiac afterload, LVDd/LVEDV, and left ventricle wall pres‐
sure [35,36]. In early stage, the cardiac changes of adaptive ventricular chamber enlargement
and myocardial hypertrophy induced by volume overload maybe reversible. Removal and
control of excess fluid with dialysis is considered critical for protection against cardiovascular
sequelae. A recent Chinese study found that antihypertensive agents including beta-blockers
may influence hemodynamics, which may limit fluid removal during hemodialysis [37].
3.2. Anemia
Anemia is predictive of morbidity and mortality from cardiovascular causes in patients with
CKD or on dialysis [38]. It leads to reduced oxygen delivery to tissues, causing organ dys‐
function. It also causes hemodynamic adaptations including a high cardiac output state to
maintain adequate tissue oxygenation leading to left ventricular dilatation and hypertro‐
phy [39]. However, at the present time, correction of anemia to hemoglobin levels above 13
g/dL (130 g/L) has not been associated with a cardiovascular or survival benefit. Mainte‐
nance of hemoglobin levels above 11 g/dL (110 g/L) is currently recommended and may
prevent further progression of LVH. Guidelines for the management of anemia and iron
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deficiency in chronic hemodialysis (HD) patients have been developed to standardize ther‐
apy and improve clinical outcome. But a recent Dutch study found that compliance with
anemia targets in stable HD patients was poor and showed a wide variation between treat‐
ment facilities [40].
3.3. Inflammation
The role of chronic inflammation as a putative cause of high mortality in ESRD has attracted
considerable interest during the last decade. It has been hypothesized that in addition to its
direct pro-atherogenic effects, chronic inflammation may serve as a catalyst and in the toxic
uremic milieu may modulate the effects of concurrent vascular and nutritional risk factors
[41]. ESRD has become a prototype for chronic inflammation. There is consistent evidence
that CRP and pro-inflammatory cytokines such as IL-1, IL-6 and TNF-α are risk factors for
atherosclerotic complications and predict death and adverse cardiovascular outcomes in
these patients [42,43,44,45]. Schwarz et al. [46] have shown that coronary atherosclerotic pla‐
ques in ESRD patients are characterized by increased medial thickness, infiltration by and
activation of macrophages and marked calcification. Available evidence suggests that heavi‐
ly calcified and inflamed plaques contribute to excessive cardiovascular risk in ESRD pa‐
tients [47]. Levels of CRP increase as the renal function deteriorates and are particularly high
in patients with ESRD. As many as one third to one half of patients with ESRD have CRP
levels in the very high-risk category, and CRP continues to be an excellent predictor of ad‐
verse outcome in this population [48]. Parekh et al. [49] prospectively studied a cohort of
more than 1,000 ESRD patients followed for a median of 2.5 years and reported that the
highest tertile of CRP was associated with a two-fold increased adjusted risk of sudden car‐
diac death compared to patients in the lowest tertile.
3.4. Oxidant stress
Numerous factors in the dialysis patient increase o xidative stress (OxStress). These include
inflammation (as marked by elevated C-reactive protein), malnutrition (by reducing antioxi‐
dant defenses), uremic toxins, and, potentially, the dialysis procedure itself. Many protective
mechanisms are impaired, including reduced plasma protein-associated free thiols such as
glutathione. This may magnify the impact of OxStress in the dialysis population. OxStress is
recognized as a critical factor in the development of atherosclerotic cardiovascular disease
(ACVD) [50,51]. According to the oxidation hypothesis of atherosclerosis, low-density lipo‐
protein (LDL) in its native state is not atherogenic [52,53]. LDL must undergo oxidative
modification before it can contribute to the initiation and progression of atherosclerosis. Da‐
ta from animal models of atherosclerosis, both diet-induced and genetically altered models,
have demonstrated the presence of oxidized LDL (oxLDL) in plasma as well as in athero‐
sclerotic lesions. Presence of oxLDL, autoantibodies against malondialdehyde-modified
LDL, and of LDL-IgG immune complexes has also been reported in human plasma and hu‐
man atherosclerotic lesions [54,55]. The pathways involved in the formation of these oxida‐
tive markers and the relationship between these markers and disease progression remain to
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be elucidated. Advanced oxidation protein products (AOPP) accumulation is a marker of
oxidative stress. A recent study in China [56] found that accumulation of AOPP was more
significant in HD compared to CAPD patients. The level of AOPP was independently associ‐
ated with ischaemic heart disease only in HD patients.
3.5. Hyperhomocysteinemia
3.5.1. Epidemiology
Hyperhomocysteinemia is much more common in dialysis patients than in the general pop‐
ulation. Homocysteine is typically measured in the plasma and normal levels range between
5 and 12 mcmol/L. In the general population, hyperhomocysteinemia is an independent risk
factor for adverse CVD outcomes and is commonly associated with deficiencies in folate and
vitamins B6 and B12. B-vitamin and folate supplementation effectively reduce homocysteine
levels in the general population and recent extensive folate supplementation in foods has
lowered the overall prevalence of hyperhomocysteinemia in the nondialysis population. Ho‐
mocysteine levels increase dramatically as kidney function declines, with as many as 80% of
dialysis patients classified as having hyperhomocysteinemia. In dialysis patients, some but
not all studies suggest that hyperhomocysteinemia is independently associated with CVD
mortality. Nutritional status confounds these analyses, since better nourished patients tend
to have higher homocysteine levels. The relationship between homocysteine levels and car‐
diovascular disease was described initially by observational studies, which may overesti‐
mate the effect of this relationship. Two meta-analyses of epidemiologic studies [57,58]
suggested that reduced homocysteine levels could lower the risk of coronary heart disease,
stroke, and cardiovascular disease. However, Bazzano et al [59] concluded that folic acid
therapy did not significantly contribute to cardiovascular disease, stroke, or myocardial in‐
farction.
3.5.2. Treatment
Folic acid supplementation may play an important role in carcinogenesis, because when it is
administered to individuals with established cancers, it potentially promotes tumor growth
[60,61]. It has also been reported that the introduction of folic acid may increase the risk of
colorectal cancer [62]. According to our review, folic acid therapy resulted in an 8% increase
in the risk of cancer, although this difference was not statistically significant. The reason for
this increase in carcinogenesis can be explained by the fact that folic acid supplementation
may affect endothelial function and support cell growth through mechanisms independent
of homocysteine [63]. Importantly, folic acid and B vitamins are water-soluble and excreted
by the kidney; therefore, therapy toxicity may be of great concern in patients with impaired
renal function. In patients with end-stage renal failure who have hyperhomocysteinemia
wherein homocysteine levels must be reduced, alternative, non-vitamin therapies are impor‐
tant. For example, enhancing urinary excretion can help to avoid a decrease in glomerular
filtration rate and an increase in major cardiovascular events [64].
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4. Ischemic heart disease
4.1. Epidemiology
Acute myocardial infarction(AMI) is common in the ESRD population. Outcomes for pa‐
tients with AMI are poor, with 50% 1-year mortality. Both atherosclerosis and atheriosclero‐
sis and arteriosclerosis contribute to pathogenesis; arteriosclerosis may cause LVH with
increased myocardial oxygen demand and altered coronary perfusion with subsequent sub‐
endocardial ischemia.
4.2. Diagnosis
Routine screening is not currently recommended. There are no preoperative screening
guidelines specific to dialysis patients, and it is reasonable to use general population guide‐
lines, recognizing that the extent of comorbid conditions prevalent in the dialysis population
is Iikely to place them into the highest cardiovascular risk group. Because many dialysis pa‐
tients are unable to achieve adequate exercise levels for valid stress tests, pharmacologic
stress test should be used in this population. Furthermore, because of the high incidence of
baseline electrocardiogram abnormalities, either nuclear or echocardiographic imaging
should be utilized in stress testing.
4.3. Prevention
Aspirin,  beta-blockers,  ACE  inhibitors,  and  nitrate  preparations  are  all  appropriate  for
primary therapy of  AMI and are  likely  appropriate  for  secondary prevention,  although
data on aspirin for secondary prevention of coronary artery disease remain inadequate to
date. Observational studies suggest that medical therapies including aspirin, beta- block‐
ers, and ACE inhibitors may be underutilized in dialysis patients. Using the ESRD data‐
base  and  the  Cooperative  Cardiovascular  Project  (CCP)  database,  Berger  AK,  et  al
[65]found  that  ESRD  patients  are  far  less  likely  than  non-ESRD  patients  to  be  treated
with aspirin, beta-blockers, and ACE inhibitors during an admission for AMI. The lower
rates of usage for these medications, particularly aspirin, may contribute to the increased
30-day mortality.
4.4. Treatment
4.4.1. Management of angina pectoris
The pharmacologic approach to angina in dialysis patients is similar to that in the general
population. The progressive introduction of sublingual nitrates, oral long-acting nitrates, be‐
ta-blockers, and calcium channel blockers is appropriate. The usual dosages of sublingual
and oral nitrates can be given to dialysis patients.
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4.4.2. Angina during the hemodialysis session
For patients whose angina manifests primarily during hemodialysis session, a number of
therapeutic options available. Nasal oxygen should be given routinely. If the anginal epi‐
sode is associated with hypotension, then initial treatment should include raising the blood
pressure by elevating the feet and by cautiously administering saline. Sublingual nitrogly‐
cerin can be given as soon as the pressure has increased to a clinically acceptable value. Con‐
sideration should be given to reducing the blood flow rate and stopping ultrafiltration until
the anginal episode subsides. Predialysis administration of 2% nitroglycerin ointment may
be of benefit when applied 1 hour prior to a hemodialysis session, assuming that the blood
pressure will tolerate this intervention.
5. Heart failure
Heart failure is the commonest manifestation of cardiac dysfunction in patients on mainte‐
nance dialysis. According to the cross-sectional survey by Harnett and coworkers, which in‐
cluded both hemodialysis and peritoneal dialysis patients, nearly one-third of the patients
developed heart failure on initiation of dialysis, of which 56% had further recurrences [66].
Even among patients with no heart failure at baseline, around 25% of patients developed
heart failure at a rate of 7% per year. In addition, the presence of heart failure was associated
with a worse prognosis in that median survival was 36 months for patients with heart fail‐
ure at baseline compared to 62 months for patients without heart failure. They also found
that increasing age, diabetes mellitus and ischemic heart disease were associated with heart
failure at initiation of dialysis, while ischemic heart disease, anemia, hypoalbuminemia and
systolic dysfunction were important predictors of heart failure recurrence [67]. The presence
of ischemic heart disease is associated with greater left atrial diameter, greater left ventricu‐
lar end-systolic diameter, lower fractional shortening and, thus, more systolic dysfunction
[68].In the Canadian Prospective Cohort Study, which included 433 incident dialysis pa‐
tients, 74% had left ventricular hypertrophy at baseline, 30% had left ventricular hypertro‐
phy with dilatation, and 15% had systolic dysfunction [69], indicating that much of the
cardiac hypertrophy and dysfunction was already established by the time patients started
their dialysis therapy. This may also explain why dialysis patients are prone to develop
heart failure.
6. Arrhythmia
Paroxysmal atrial fibrillation attack is one of most common tachyarrhythmia in MHD pa‐
tients. Paroxysmal atrial fibrillation attack not only can affect the dialysis to proceed
smoothly, but also it can increase the death risk in MHD patients. In the Dialysis Outcomes
and Practice Patterns Study [70], which analyzed 37,765 participants in 12 countries in the
Dialysis Outcomes and Practice Patterns Study to explore the association of the following
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practices with sudden death (due to cardiac arrhythmia, cardiac arrest, and/or hyperkale‐
mia): treatment time [TT] <210 minutes, Kt/V <1.2, ultrafiltration volume >5.7% of postdialy‐
sis weight, low dialysate potassium [K(D) <3 mEq/L]), and prescription of Q wave/T wave
interval-prolonging drugs,indicating that identified modifiable dialysis practices associated
with higher risk of sudden death, including short TT, large ultrafiltration volume, and low
K(D). Because K(D) <3 mEq/L is common and easy to change, K(D) tailoring may prevent
some sudden deaths. Individualized interventions may effectively reduce paroxysmal atrial
fibrillation attack during dialysis in MHD patients. The general individualized intervention
in MHD patients are, (1) individualized dialysis programmes, such as increasing the dialysis
or hemodialysisfiltrition frequency or be changed to daily dialysis for atrial fibrillation with
frequent seizure. Regular monitoring of serum potassium levels before and post dialysis, ad‐
justing dialysate concentration of potassium ions in a timely manner, using different pre‐
scription of individualized dialysate for hemodialysis treatment. (2)Behavioral
interventions, such as improving their way of life to develop good habits and patterns of di‐
alysis. (3) Closely monitoring the patients’ vital signs during hemodialysis, such as heart
rate, blood pressure and pulse rate. (4) Controlling interdialytic weight gain (IDWG), strict
volume policy including salt restriction and adequate ultrafiltration is fundamental to reach
normovolemia/normotension together with regression of left atrial hypertrophy in patients
on hemodialysis. In HD patients, IDWG is significantly associated with left atrial volume/
diameter. Together with better volume control, left atrium volume must be decreased. Most
importantly, they should focus on salt restriction not water restriction. (5) Psychological in‐
tervention to reduce sympathetic excitement to induce atrial fibrillation.
7. Conclusion
A high prevalence of cardiovascular disease is observed in ESRD patients receiving dialysis
therapy. This usually constitutes a combination of vascular and myocardial disease related
to both traditional and nontraditional risk factors. Most of these cardiovascular complica‐
tions are already established and advanced by the time patients are started on dialysis treat‐
ment, thus indicating the need for earlier and more active screening for cardiovascular
disease even before patients progress to end-stage kidney disease. More attention should be
focused on improving cardiovascular outcomes in ESRD patients receiving maintenance di‐
alysis therapy.
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